Phocas Financial Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Phocas Financial Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$116K	–	312
2022 Q4	$116K	Buy	+400	New	+$122K	0.02%	206
2019 Q3	–	Sell	-400	Closed	-$73K	–	276
2019 Q2	$73K	Buy	+400	New	+$69.9K	0.01%	234
2019 Q1	–	Sell	-400	Closed	-$66K	–	290
2018 Q4	$66K	Buy	+400	New	+$69.3K	0.01%	233

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Phocas Financial Corp's VRTX Position: Q1 2023 in Review

Phocas Financial Corp sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 400 shares — an estimated $116K sold.

Phocas Financial Corp first reported a position in VRTX in Q4 2018 and held it in 3 quarters. The position peaked at $116K in Q4 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Phocas Financial Corp reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Phocas Financial Corp sold 400 Vertex Pharmaceuticals shares in Q1 2023, an estimated $116K.
Phocas Financial Corp first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Phocas Financial Corp's Vertex Pharmaceuticals position peaked at $116K in Q4 2022.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Phocas Financial Corp's 13F filing for Q1 2023, filed 13 Apr 2023.